PDCD1 and hepatitis A virus infection: Checkpoint inhibitor-induced hepatitis occurred in 30 (1.8%) patients treated with PD-1 inhibition, 29 (2.6%) patients treated with ipilimumab and in 80 (20.7%) patients treated with combination therapy.